Literature DB >> 11224359

The anti-ischaemic drug, eliprodil, blocks hyperactivity induced by intra-accumbens injection of spermine.

D.J. Sanger1, G. Perrault, E. Audi.   

Abstract

NMDA receptor mechanisms in the nucleus accumbens play an important role in the control of locomotor activity. Among the several binding sites associated with these receptors, the polyamine-sensitive sites have received relatively little attention. It has recently been shown, however, that the anti-ischaemic drug eliprodil NMDA antagonist effects probably mediated by activity at this polyamine site. In the present series of experiments the effects of injections of spermine and eliprodil into the nucleus accumbens of rats were investigated. Locomotor hyperactivity was produced by intra-accumbens injection of spermine, phencyclidine and AP7. Phencyclidine, but not AP7, produced a similar effect after systemic injection. Eliprodil did not increase locomotion after either intra-accumbens or i.p. administration. However, systemic injection of eliprodil (5, 10, 20mg/kg) produced a dose-related antagonism of hyperactivity induced by intra-accumbens spermine, but not by systemic or intra-accumbens injection of d-amphetamine. These results provide the first behavioural demonstration of the polyamine antagonist properties of eliprodil, and further emphasise the differences between the pharmacological profile of eliprodil and those of other NMDA antagonists.

Entities:  

Year:  1995        PMID: 11224359

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  1 in total

1.  Pharmacological and genetic evidence indicates that combined inhibition of NR2A and NR2B subunit containing NMDA receptors is required to disrupt prepulse inhibition.

Authors:  Will Spooren; Cedric Mombereau; Martine Maco; Rammy Gill; John A Kemp; Laurence Ozmen; Shigetada Nakanishi; Guy A Higgins
Journal:  Psychopharmacology (Berl)       Date:  2004-02-20       Impact factor: 4.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.